Tandem Diabetes Care (TNDM) Net Equity Issued and Repurchased (2013 - 2024)

Tandem Diabetes Care (TNDM) has reported Net Equity Issued and Repurchased for 12 consecutive years, with $2.3 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Net Equity Issued and Repurchased fell 12.04% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2024 stood at -$6.7 million (down 260.85% YoY), and the FY2024 full-year result was -$6.7 million, down 260.85% from the prior year.
• Net Equity Issued and Repurchased improved to $2.3 million in Q4 2024 per TNDM's latest filing, from -$4.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $29.0 million in Q3 2020 and bottomed at -$4.5 million in Q3 2024.
• Historically, Net Equity Issued and Repurchased has averaged $6.7 million across 5 years, with a median of $3.7 million in 2022.
• The sharpest annual moves came in 2020 and 2023: Net Equity Issued and Repurchased soared 504.53% in 2020, then plunged 398.64% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $9.2 million in 2020, then surged by 72.89% to $15.9 million in 2021, then sank by 61.6% to $6.1 million in 2022, then tumbled by 57.1% to $2.6 million in 2023, then slipped by 12.04% to $2.3 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $2.3 million, -$4.5 million, and -$3.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.